title: Targeting the lung using siRNA and antisense based oligonucleotides.
abstract: The accessibility to topical administration through inhalation, combined with its large surface area, has led to speculation that the lung might offer an ideal target for the application of oligonucleotide based therapeutics. In this review, we shall critically examine the challenges facing antisense and siRNA based approaches for target validation in vivo and as potential therapeutics. In particular, we shall discuss the antisense and siRNA based approaches in relation to factors such as delivery, distribution, stability, off-target effects, unwanted immune responses and the selection of the optimum mRNA targets.
authors.affiliation: Respiratory Research Group, Wythenshawe Hospital, School of Translational Medicine, University of Manchester, M23 9LT, UK.
authors.forename: Sterghios A
authors.initials: SA
authors.lastname: Moschos
authors.forename: Karen
authors.initials: K
authors.lastname: Spinks
authors.forename: Andrew E
authors.initials: AE
authors.lastname: Williams
authors.forename: Mark A
authors.initials: MA
authors.lastname: Lindsay
mesh_terms: D000818:Animals; D016503:Drug Delivery Systems; D006801:Humans; D008168:Lung / Q000187:drug effects*; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D016376:Oligonucleotides, Antisense; D034741:RNA, Small Interfering